Clinical trials: DLBCL
Diffuse Large B-cell Lymphoma (DLBCL)
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy.
- Trial name
- OLYMPIA-3 (NCT06091865)
- Testing
- Odronextamab, Rituximab, Cyclophosphamide
- Where
- 194 sites in United States, Australia and 19 more
- Volunteers
- 904 people
- Sponsor
- Regeneron Pharmaceuticals
DLBCL, High-grade B-cell Lymphoma (HGBCL)
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
The purpose of this trial is to measure the following in participants with relapsed and/or refractory B-cell lymphoma who receive epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20): The dose schedule…
- Conditions
- DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL
- Trial name
- EPCORE™ NHL-1 (NCT03625037)
- Testing
- Epcoritamab
- Where
- 85 sites in United States, Australia and 13 more
- Volunteers
- 666 people
- Sponsor
- Genmab
NHL, DLBCL - Diffuse Large B Cell Lymphoma
Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL
A phase II, multi-center study to compare the feasibility, and clinical efficacy of local manufacturing of CD19-directed CAR T-cells (ARI-0001 CAR T-cells) with commercial produced CAR T-cells (for example axicabtagene…
- Trial name
- HOVON161 (NCT05641428)
- Testing
- ARI-0001, Axi-cel
- Where
- 7 sites in Netherlands
- Volunteers
- 340 people
- Sponsor
- University Medical Center Groningen
Non-Hodgkin's B-cell Lymphoma, Lymphoma Non-Hodgkin
Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma
A Phase II, open-label, two-arm, multicenter study evaluating the combination of epcoritamab with R-CHOP chemotherapy in patients with newly diagnosed, aggressive B-cell non-Hodgkin lymphoma.
- Conditions
- Non-Hodgkin's B-cell Lymphoma, Lymphoma Non-Hodgkin, Diffuse Large B-Cell Lymphoma (DLBCL)
- Trial name
- NCT07588698
- Testing
- Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone (R-CHOP), Epcoritamab, Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Carrie Ho, MD
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization
Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization
This is a multicenter, prospective, single-arm, phase II clinical study evaluating the early prophylactic use of recombinant human thrombopoietin (rhTPO) to prevent thrombocytopenia associated with the EAP regimen for…
- Conditions
- Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization, Chemotherapy-Induced Thrombocytopenia
- Trial name
- NCT07848672
- Testing
- rhTPO prophylaxis plus EAP stem-cell mobilization
- Volunteers
- 70 people
- Sponsor
- The Affiliated People's Hospital of Ningbo University
NHL, DLBCL
The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL
The prognosis of Diffuse Large B cell Lymphoma (DLBCL) patients with an early relapse is dismal. Atezolizumab has shown promising activity in relapsed DLBCL patients.
- Trial name
- HO151DLBCL (NCT03463057)
- Testing
- Atezolizumab
- Where
- 32 sites in Belgium, Netherlands
- Volunteers
- 109 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
DLBCL - Diffuse Large B Cell Lymphoma
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
Patients treated for DLBCL are at high risk of developing AICD. This adverse event is characterized by irreversible damage to the heart muscle with a loss of cardiomyocytes and subsequent decline in cardiac pumping capacity.
- Trial name
- HO170DLBCL (NCT06220032)
- Testing
- Dexrazoxane, Rituximab, Cyclophosphamide
- Where
- 25 sites in Netherlands
- Volunteers
- 324 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
Long-term follow-up of patients exposed to an AUTO CAR T cell therapy for up to 15 years following their first AUTO CAR T cell therapy infusion.
- Conditions
- Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma, DLBCL, ALL, Adult and Pediatric
- Trial name
- NCT03628612
- Testing
- AUTO CAR T cell therapy
- Where
- 9 sites in United States, Spain and 1 more
- Volunteers
- 500 people
- Sponsor
- Autolus Limited
Non Hodgkin Lymphoma (NHL), Diffuse Large B-cell Lymphoma (DLBCL)
Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy
This study will evaluate the ability of a largely self-administered geriatric assessment (GA) to predict toxicity in non-Hodgkin Lymphoma (NHL) patients ≥60 years old receiving chemotherapy or chemoimmunotherapy.
- Trial name
- NCT01829958
- Testing
- rituximab, prednisone, Geriatric Assessment
- Where
- 8 sites in United States
- Volunteers
- 201 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
DLBCL, Lymphoma, B-Cell
A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
The purpose of this study is to test the effectiveness and safety of polatuzumab vedotin in combination with R-miniCHP in patients 75 years and older with DLBCL.
- Trial name
- NCT04594798
- Testing
- Polatuzumab vedotin, Rituximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Rochester
Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma
CAR-T Followed by Bispecific Antibodies
The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab (Cohort 1) or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells.
- Trial name
- NCT04889716
- Testing
- mosunetuzumab, glofitamab, obinutuzumab
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)
CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
The goal of this study is to treat patients diagnosed with relapsed or refractory positive B cell lymphoma - positive for 2 or more target antigens - with CAR19.20.22 CAR T-cells.
- Conditions
- B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), Follicular Lymphoma
- Trial name
- NCT07168486
- Testing
- CD19.20.22 CAR T cells, Fludarabine and Cyclophosphamide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Maryland, Baltimore
Mediastinal Lymphoma, Hodgkin Disease Lymphoma
Proton Therapy for Mediastinal Lymphoma (PROMLY)
The study aims to investigate whether proton therapy is feasible in a national setting and whether proton therapy can reduce the risk of late toxicity (secondary cancers and heart toxicity) compared to foton therapy.
- Conditions
- Mediastinal Lymphoma, Hodgkin Disease Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)
- Trial name
- PROMLY (NCT07817641)
- Testing
- Proton therapy
- Where
- Denmark
- Volunteers
- 139 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)
Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors
This is a prospective randomized open-label, multicenter, 2-arm study to assess the role of healthy LifeStyle implemented Survivorship Care Plan (LS-SCP) in modifying the Quality of Life (QoL) in a population of long-term…
- Conditions
- Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL)
- Trial name
- NCT05934084
- Testing
- Lifestyles Implemented-Survivorship Care Plan (LS-SCP)
- Where
- 40 sites in Italy
- Volunteers
- 552 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Diffuse Large B-cell-lymphoma, DLBCL, Nos Genetic Subtypes
Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma
This study is to investigate the safety and tolerability of C402-CD19-CAR treatment in subjects with relapsed or refractory large B-cell lymphoma and further determine the recommended Phase 2 dose of C402-CD19-CAR.
- Conditions
- Diffuse Large B-cell-lymphoma, DLBCL, Nos Genetic Subtypes, Follicular Lymphoma Grade 3B, PMBL
- Trial name
- C402 (NCT06830031)
- Testing
- C402-CD19-CAR
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Exuma Biotechnology Ltd.
Pirtobrutinib, Immunochemotherapy
Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement
This is an open-label, prospective, single-arm, multicenter study designed to evaluate the efficacy and safety of MTX plus pirtobrutinib combined with routinely-used clinical chemoimmunotherapy regimens in patients with DLBCL and…
- Conditions
- Pirtobrutinib, Immunochemotherapy, DLBCL - Diffuse Large B Cell Lymphoma, CNS Involvement of Systemic Lymphoma
- Trial name
- NCT07812493
- Testing
- pirtobrutinib+MTX+immunolchemotherapy
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Pengpeng Xu
DLBCL
A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
This is a multicenter, open-label phase Ib study, evaluating the safety, tolerability, preliminary efficacy and PK characteristics of Rocbrutinib (LP-168) combined with R-GemOx in patients with R/R non-GCB DLBCL.
- Trial name
- NCT07570017
- Testing
- Rocbrutinib, R-GemOx
- Where
- 2 sites in China
- Volunteers
- 42 people
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Refractory Large B-cell Lymphoma (LBCL)
Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy
The goal of this Phase 2, open-label, multicenter clinical trial is to assess the efficacy and safety of accelerated ramp-up and fixed-dose subcutaneous epcoritamab combined with lenalidomide in adults with relapsed or refractory…
- Conditions
- Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Refractory Large B-cell Lymphoma (LBCL), Refractory T-cell/Histiocyte-rich Large B-cell Lymphoma, Refractory Transformed Follicular Lymphoma
- Trial name
- BiFAST (NCT07814001)
- Testing
- Epcoritamab, Lenalidomide
- Where
- 15 sites in France
- Volunteers
- 55 people
- Sponsor
- The Lymphoma Academic Research Organisation
Blood Cancers, Leukemia
A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In Greece
This clinical trial aims to determine whether a manualised group intervention for people with blood cancers can help them experience positive psychological changes following their diagnosis, known as post-traumatic growth.
- Conditions
- Blood Cancers, Leukemia, Lymphoma, Bone Marrow Transplant
- Trial name
- NCT07814170
- Testing
- A manualised post-traumatic growth intervention for people with hematological cancers
- Where
- 2 sites in Greece
- Volunteers
- 80 people
- Sponsor
- University of West Attica
DLBCL
Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance
This is a prospective, multicenter, single arm, phase II trial in patients with ≥ 18 and <65 years with poor-prognosis (IPI ≥ 2) and newly diagnosed ABC-DLBCL.
- Trial name
- NCT03731234
- Testing
- Ibrutinib
- Where
- 39 sites in Italy
- Volunteers
- 75 people
- Sponsor
- Fondazione Italiana Linfomi - ETS